Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparable results were obtained when shorter 13-mer tc-DNA AONs were used in a similar study setup in mdx/bl10 mice (Relizani et al., 2017).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Relizani et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Research works printed but not linked: 42
- Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol., 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
- Goemans, 2011, Systemic administration of PRO051 in Duchenne’s muscular dystrophy, N. Engl. J. Med., 364, 1513, 10.1056/NEJMoa1011367 · DOI · Paper page
- Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 · DOI · Paper page
- Mostacciuolo, 1987, Population data on benign and severe forms of X-linked muscular dystrophy, Hum. Genet., 75, 217, 10.1007/BF00281062 · doi:10.1007/bf00281062
- van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N. Engl. J. Med., 357, 2677, 10.1056/NEJMoa073108 · DOI · Paper page
- Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol., 8, 918, 10.1016/S1474-4422(09)70211-X · DOI · Paper page
- Aartsma-Rus, 2017, FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga, Nucleic Acid Ther., 27, 1, 10.1089/nat.2016.0657 · DOI · Paper page
- Lu, 2014, What can we learn from clinical trials of exon skipping for DMD?, Mol. Ther. Nucleic Acids, 3, e152, 10.1038/mtna.2014.6 · DOI
- Straub, 2016, Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy, Lancet Neurol., 15, 882, 10.1016/S1474-4422(16)30035-7 · DOI
- Stein, 2016, Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice, Mol. Ther., 24, 1884, 10.1038/mt.2016.188 · DOI · Paper page
- Goyenvalle, 2015, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat. Med., 21, 270, 10.1038/nm.3765 · DOI · Paper page
- Goyenvalle, 2016, Therapeutic potential of Tricyclo-DNA antisense oligonucleotides, J Neuromuscul Dis, 3, 157, 10.3233/JND-160146 · doi:10.3233/jnd-160146
- Renneberg, 2002, Watson-Crick base-pairing properties of tricyclo-DNA, J. Am. Chem. Soc., 124, 5993, 10.1021/ja025569+ · DOI
- Ittig, 2011, Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes, Nucleic Acids Res., 39, 373, 10.1093/nar/gkq733 · DOI
- Renneberg, 2002, Antisense properties of tricyclo-DNA, Nucleic Acids Res., 30, 2751, 10.1093/nar/gkf412 · doi:10.1093/nar/gkf412
- Murray, 2012, TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry, Nucleic Acids Res., 40, 6135, 10.1093/nar/gks273 · DOI · Paper page
- Moulton, 2010, Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy, Biochim. Biophys. Acta, 1798, 2296, 10.1016/j.bbamem.2010.02.012 · DOI · Paper page
- Frazier, 2014, Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide, Toxicol. Pathol., 42, 923, 10.1177/0192623313505781 · doi:10.1177/0192623313505781
- Aartsma-Rus, 2014, Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges, Nucleic Acid Ther., 24, 1, 10.1089/nat.2014.1500 · DOI
- Godfrey, 2017, Delivery is key: lessons learnt from developing splice-switching antisense therapies, EMBO Mol. Med., 9, 545, 10.15252/emmm.201607199 · DOI
- Mann, 2002, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, J. Gene Med., 4, 644, 10.1002/jgm.295 · DOI
- Kohler, 2005, Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy, Am. J. Respir. Crit. Care Med., 172, 1032, 10.1164/rccm.200503-322OC · DOI · Paper page
- Lidov, 1993, The distribution of dystrophin in the murine central nervous system: an immunocytochemical study, Neuroscience, 54, 167, 10.1016/0306-4522(93)90392-S · DOI · Paper page
- Knuesel, 2000, Differential expression of utrophin and dystrophin in CNS neurons: an in situ hybridization and immunohistochemical study, J. Comp. Neurol., 422, 594, 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q · DOI
- Miranda, 2015, Altered social behavior and ultrasonic communication in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy, Mol. Autism, 6, 60, 10.1186/s13229-015-0053-9 · DOI · Paper page
- Sekiguchi, 2009, A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice, Brain, 132, 124, 10.1093/brain/awn253 · DOI · Paper page
- Frazier, 2015, Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective, Toxicol. Pathol., 43, 78, 10.1177/0192623314551840 · DOI · Paper page
- Henry, 2002, Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide, Int. Immunopharmacol., 2, 1657, 10.1016/S1567-5769(02)00142-X · DOI
- Agrawal, 2004, Role of Toll-like receptors in antisense and siRNA [corrected], Nat. Biotechnol., 22, 1533, 10.1038/nbt1042 · DOI
- Dirin, 2013, Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides, Expert Opin. Biol. Ther., 13, 875, 10.1517/14712598.2013.774366 · DOI · Paper page
- Swayze, 2007, Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals, Nucleic Acids Res., 35, 687, 10.1093/nar/gkl1071 · DOI · Paper page
- Vaidya, 2008, Biomarkers of acute kidney injury, Annu. Rev. Pharmacol. Toxicol., 48, 463, 10.1146/annurev.pharmtox.48.113006.094615 · DOI · Paper page
- Zhang, 2015, The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse, Toxicol. Rep., 2, 838, 10.1016/j.toxrep.2015.05.008 · DOI
- Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Hum. Mutat., 36, 395, 10.1002/humu.22758 · DOI · Paper page
- Ittig, 2004, Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA, Nucleic Acids Res., 32, 346, 10.1093/nar/gkh187 · DOI
- Chaussenot, 2015, Cognitive dysfunction in the dystrophin-deficient mouse model of Duchenne muscular dystrophy: a reappraisal from sensory to executive processes, Neurobiol. Learn. Mem., 124, 111, 10.1016/j.nlm.2015.07.006 · DOI · Paper page
- Kamola, 2015, In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization, Nucleic Acids Res., 43, 8638, 10.1093/nar/gkv857 · DOI · Paper page
- Lindow, 2012, Assessing unintended hybridization-induced biological effects of oligonucleotides, Nat. Biotechnol., 30, 920, 10.1038/nbt.2376 · DOI
- Zhou, 2008, Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium, Toxicol. Sci., 101, 159, 10.1093/toxsci/kfm260 · DOI · Paper page
- Goyenvalle, 2012, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Hum. Mol. Genet., 21, 2559, 10.1093/hmg/dds082 · DOI
- Mattison, 2012, Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in mice, Pediatr. Nephrol., 27, 469, 10.1007/s00467-011-2001-z · DOI
- Aartsma-Rus, 2003, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum. Mol. Genet., 12, 907, 10.1093/hmg/ddg100 · DOI · Paper page
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Relizani, K., Griffith, G., Echevarría, L., Zarrouki, F., Facchinetti, P., Vaillend, C., Leumann, C., Garcia, L., & Goyenvalle, A.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 8
- Pages
- 144-157
- ISSN
- 2162-2531
- Cited by
- 83
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Agence Nationale de la Recherche (ANR-14-CE13-0037)
- Duchenne Parent Project
- Association Française contre les Myopathies
- Institut National de la Santé et de la Recherche Médicale
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model. https://app.cochat.ai/papers/10.1016/j.omtn.2017.06.013
- The paper
- Relizani, K., Griffith, G., Echevarría, L., Zarrouki, F., Facchinetti, P., Vaillend, C., Leumann, C., Garcia, L., & Goyenvalle, A. (2017). Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model. Molecular Therapy - Nucleic Acids. https://doi.org/10.1016/j.omtn.2017.06.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.